TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04815317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditive stimulation
Description: The auditory stimulation will consist of listening to relaxing pieces of music from MP3 files from the International Center for Music Therapy (Noisy le Grand, France).~Listening will be done through noise-cancelling headphones (PLANTRONICS, Gamecom 780, Santa Cruz, California, USA) for 10 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensitive stimulation
Description: Sensitive stimulation will consist of administering fresh air to the patient's face by means of a fan without blades (DYSON AM01, Malmesbury, UK) for 10 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auditory control
Description: The auditory control condition will consist of listening to a pink noise. The pink noise, like the white noise, is a normalized noise. The sound produced on a TV set that is out of adjustment during the snow effect is a representative example of such noise. Pink noise is a random signal whose power spectral density decreases by 3dB per octave. This signal is closer to the sensitivity of the ear than white noise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sensitive control
Description: The sensitive control condition will be achieved by administering fresh air on the calf.
Study: NCT02891343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2-hour period of hypoxia
Description: During this period, the FiO2 will be set on 21% (normoxia condition). A filter will be put between the mask and the tubes connecting it to the machine generating hypoxia (equipment reference = Altitrainer NP190). On that filter a gas analyser will monitor the FiO2 and a capnography monitor (Capnostream 20, ORIDION) will also be installed.
Study: NCT02041923

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: H-HOPE
Description: Infant remediation using a developmentally appropriate multisensory intervention addresses the specific behavioral organization needs of premature infants. Maternal redefinition and re-education by a nurse-community advocate team uses participatory guidance to address the needs of mothers of premature infants.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attention Control
Description: Mothers received equal amount of attention from the team. Attention consisted of additional teaching regarding premature infant care.
Study: NCT02750176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed chain exercises
Description: Closed-chain strengthening will be performed with the shoulder moving over a fixed hand. Resistance will be provided by body weight against gravity. To off-load and progress the amount of body-weight resistance, elastic bands will be used to support body weight using a exercise frame. Patients will perform 6 exercises.
Study: NCT02956434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Family Intervention
Description: Two 50-minute sessions aimed at helping family members be most supportive to their loved one's treatment goals.
Study: NCT03970993

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 Matrix-M vaccination
Description: Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 Matrix-M vaccination
Description: Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 Matrix-M vaccination
Description: Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 Matrix-M vaccination
Description: Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 Matrix-M vaccination
Description: Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 Matrix-M vaccination and CHMI
Description: Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly. Volunteers then have the option to be challenged with malaria by mosquito bite

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 Matrix-M vaccination and CHMI
Description: Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly. Volunteers then have the option to be challenged with malaria by mosquito bite

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 Matrix-M vaccination and CHMI
Description: Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly. Volunteers then have the option to be challenged with malaria by mosquito bite

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 Matrix-M vaccination and CHMI
Description: Three dose vaccination of 2μg, 10μg or 50μg of R21 and 50ug Matrix-M delivered intramuscularly. Volunteers then have the option to be challenged with malaria by mosquito bite

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 Matrix-M vaccination booster
Description: Optional R21 Matrix-M vaccination booster following a three dose vaccination schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 Matrix-M vaccination booster
Description: Optional R21 Matrix-M vaccination booster following a three dose vaccination schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 Matrix-M vaccination booster
Description: Optional R21 Matrix-M vaccination booster following a three dose vaccination schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21 Matrix-M vaccination booster
Description: Optional R21 Matrix-M vaccination booster following a three dose vaccination schedule
Study: NCT03346213

Intervention type: DRUG
Intervention: MonoFer
Description: Anaemic patients undergoing major surgery who would routinely be receiving intravenous iron 'MonoFer' will get this as part of routine care. They will then have a CPET repeated at least 10 days afterwards.
Study: NCT00621296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424 (Telaprevir)
Description: Three tablets of MP-424 250mg tablet at a time, every 8 hours, 24 weeks administration (dose in a day: 2250 mg)
Study: NCT03443713

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 CGM
Description: Subjects will wear a Dexcom G6 CGM for the 28 days they are on study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 CGM
Description: Subjects will wear a Dexcom G6 CGM for the 28 days they are on study.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 CGM
Description: Subjects will wear a Dexcom G6 CGM for the 28 days they are on study.
Study: NCT03374657

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPK850
Description: In one of 4 dose levels administered via subretinal injection under anesthesia

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPK850
Description: In one of 4 dose levels administered via subretinal injection under anesthesia

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPK850
Description: In one of 4 dose levels administered via subretinal injection under anesthesia

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPK850
Description: In one of 4 dose levels administered via subretinal injection under anesthesia
Study: NCT01754363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Attune Primary Total Knee Replacement
Description: Patients will undergo a primary total knee replacement using one of the four configurations of the Attune knee (CR FB, CR RP, PS FB, PS RP).
Study: NCT03390504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Participants will swallow erdafitinib tablets orally at a starting dose of 8 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinflunine
Description: Participants will receive vinflunine 320 mg/m\^2 as a 20-minute intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel 75 mg/m\^2 as a 1 hour intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Participants will receive pembrolizumab 200 mg as a 30-minute intravenous infusion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)
Description: FGFRi CTA will be used to determine molecular eligibility.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)
Description: FGFRi CTA will be used to determine molecular eligibility.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)
Description: FGFRi CTA will be used to determine molecular eligibility.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibroblast Growth Factor Receptor inhibitor Clinical Trial Assay (FGFRi CTA)
Description: FGFRi CTA will be used to determine molecular eligibility.
Study: NCT03652064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab (1800 mg) will be administered by SC injection once every week for Cycles 1 to 2, then every 3 weeks for Cycles 3-8. For Cycle 9 and beyond, participants will receive daratumumab 1800 mg SC once every 4 weeks until documented disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m\^2 will be administered by SC injection twice weekly on Days 1, 4, 8, and 11 of each 21-day cycle for Cycles 1-8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m\^2 will be administered by SC injection twice weekly on Days 1, 4, 8, and 11 of each 21-day cycle for Cycles 1-8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide will be self-administered at a dose of 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 and beyond until disease progression or unacceptable toxicity whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be self-administered at a dose of 25 mg orally on Day 1 to Day 14 for Cycles 1 through 8 and on Days 1 to 21 for Cycle 9 and beyond until disease progression or unacceptable toxicity whichever occurs first.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be self-administered orally, 20 mg on Days 1, 2, 4, 5, 8, 9, 11, 12 of each 21-day cycle for Cycles 1-8. During Cycle 9 and beyond dexamethasone, will be self-administered orally at a total dose of 40 mg on Days 1, 8, 15, 22 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be self-administered orally, 20 mg on Days 1, 2, 4, 5, 8, 9, 11, 12 of each 21-day cycle for Cycles 1-8. During Cycle 9 and beyond dexamethasone, will be self-administered orally at a total dose of 40 mg on Days 1, 8, 15, 22 of each 28-day cycle.
Study: NCT03314740

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Comparator active compound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Experimental compound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: Experimental compound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Experimental compound

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Experimental compound
Study: NCT00880308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Study: NCT02649062

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NGM282

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04491292

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT01439659

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutritional Counseling
Description: Initial interview and subsequent telephone contact once per week for two months, once every other week for the following two months, and once per month for the remaining two months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily Supplements
Description: Two capsules daily in the morning and two capsules daily in the evening of Juice Plus+ in addition to regular meal. Also a beverage, Juice Plus+ Complete (a powder mixture to be added to one cup of fluid) daily in the evening.
Study: NCT02320643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seratom® PA mesh
Description: Partially absorbable mesh
Study: NCT03387202

Intervention type: PROCEDURE
Intervention: Laparoscopic lateral suspension with mesh
Description: V-shaped ccm wide and 25cm length mesh strip is prepared from a 30x30cm Prolene mesh (Ethicon J\&J).Deep dissection of the uterovesical space is performed.Cutaneous incisions are bilaterally made 3cmsuperoposterior to the anteriosuperior iliac spine.A grasper is introduced retroperitoneally through the subperitoneum holding the beginning part of mesh until reaching the vesicovaginal space in an oblique route rather than transverse.Broad ligament is lifted upward and tunnel is practiced in its lower third.Assistant grasper catches the distal mesh and pulls out through the opposite subperitoneal tunnel.Corner of mesh is fixed to the pubocervical fascia,uterine cervix and isthmus with Absorba Tack™(Covidien, Mansfield,USA).Tension-free lateral mesh suspension is achieved at the desired level

Intervention type: DIAGNOSTIC_TEST
Intervention: Transperineal ultrasound
Description: Vaginal length, bladder neck mobility and pelvic floor biometry with anterioposterior hiatal diameter and pelvic organ descent measurements are measured by transperineal ultrasonography to assess anatomic success in the preoperative and at postoperative first third and sixth months if available.
Study: NCT04235582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App + Inputs Contingency Management
Description: The app has programmed contingencies whereby incentives can be earned for behaviors that are inputs to abstaining from drug use (e.g., attending psychotherapy or taking SUD psychopharmacology).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App + Inputs Contingency Management
Description: The app has programmed contingencies whereby incentives can be earned for behaviors that are inputs to abstaining from drug use (e.g., attending psychotherapy or taking SUD psychopharmacology).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App + Outcomes Contingency Management
Description: The app has programmed contingencies whereby incentives can be earned for outcomes of abstaining from drug use (e.g., drug-negative saliva samples on saliva opioid tests).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App + Outcomes Contingency Management
Description: The app has programmed contingencies whereby incentives can be earned for outcomes of abstaining from drug use (e.g., drug-negative saliva samples on saliva opioid tests).
Study: NCT04513951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: phase II

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-leucovorin
Description: phase II

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: phase II

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: phase II

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: phase II

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: phase II
Study: NCT02845375

Intervention type: DRUG
Group type: OTHER
Intervention: Neostigmine
Description: Neostigmine will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
Study: NCT01774071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr- DFO-MSTP2109A
Description: If you are enrolled onto Group 1:~Once you are given the diagnostic agent, the following procedures will be done:~PET scans at the approximate times:~* 1-4 hours after the injection~* 24 hours after the injection (the next day, Day 2)~* 48-120 hours after the injection (on either Day 3, 4, or 5)~* 144-168 hours after the injection (on either Day 6, 7, or 8) You will also have research bloods drawn on the following times and days,~* Day 1: before the injection, approximately 5 minutes after, 30 minutes after, 1 hour after and 2-4 hours after the injection.~* At each time of your scheduled PET scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr DFO-MSTP2109A
Description: If you are enrolled onto Group 2:~Once you are given the study drug, the following procedures will be done:~You will have one PET scan done. The timing of the PET scan will be determined at the time of your enrollment (\~ 3-7 days after injection).~No research blood work will be drawn in Group 2
Study: NCT03880955

Intervention type: DEVICE
Intervention: ReUnion RSA System
Description: The ReUnion RSA System is designed as a reverse total shoulder endoprosthesis to address unrepairable gross rotator cuff tear, rotator cuff arthropathy with pseudoparalysis of the shoulder joint, advanced arthritic and rheumatic disorders affecting the shoulder joint, and failed previous shoulder arthroplasty. The ReUnion RSA System is comprised of a Humeral Cup, Humeral Insert, Glenosphere, Glenoid Baseplate and Screws. The intended purposes of the ReUnion RSA System are to achieve pain relief, improvement of range of motion and restoration or improvement of the shoulder function while ensuring long-term replacement of the shoulder joint with sufficient stability of all endoprosthesis components.
Study: NCT04603911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: The liposomal bupivacaine used in the research study has been approved by the U.S. Food and Drug Administration (FDA) for use in humans for pain management. The specific approved uses are postsurgical single-dose wound infiltration analgesia and brachial plexus nerve block. In this study, we will be using liposomal bupivacaine in an additional way by infiltrating liposomal bupivacaine in a tissue plane to numb the nerves that provide sensation over the chest.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine, epinephrine, dexamethasone, and clonidine
Description: The medications that are typically administered as a solution in this block include bupivacaine, epinephrine, dexamethasone, and clonidine.
Study: NCT04062162

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking football training
Description: Intervention will involve 3 sessions per week of a structured and supervised walking football program over 16 weeks. Each session will include a warm-up, followed by the practice of specific exercises where specific technical skills (pass, dribble, shot), motor skills (agility, coordination, balance) and physical fitness (cardiorespiratory and musculoskeletal capacity) will be enhanced, ending with a structured game (7x7) of walking football and a cooldown.
Study: NCT02720263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4345
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP4345
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Oral
Study: NCT02957968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2 once every 2 weeks for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2 once every 2 weeks for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2 once every 2 weeks for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cyclophosphamide 600 mg/m2 (AC) once every 2 weeks for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cyclophosphamide 600 mg/m2 (AC) once every 2 weeks for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: cyclophosphamide 600 mg/m2 (AC) once every 2 weeks for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 IV once weekly for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 IV once weekly for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 IV once weekly for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin IV 1.5 area under curve (AUC) once weekly for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin IV 1.5 area under curve (AUC) once weekly for 12 weeks.
Study: NCT00743223

Intervention type: OTHER
Intervention: The measure of the cervical posture
Description: The investigation of the cervical position consisted of locating the individual in side view with the parallel feet in erect position and tracing an imprisoned plumb wire to the ceiling and tangent to the kyphosis curve of the thoracic column. With a ruler it was verified at a distance of this line until the point deepest of the cervical lordosis curve.

Intervention type: OTHER
Intervention: The measure of the cervical posture
Description: The investigation of the cervical position consisted of locating the individual in side view with the parallel feet in erect position and tracing an imprisoned plumb wire to the ceiling and tangent to the kyphosis curve of the thoracic column. With a ruler it was verified at a distance of this line until the point deepest of the cervical lordosis curve.
Study: NCT02957968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04128969

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CS+
Description: Oral carnitine supplementation